Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

84 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry.
Abonour R, Wagner L, Durie BGM, Jagannath S, Narang M, Terebelo HR, Gasparetto CJ, Toomey K, Hardin JW, Kitali A, Gibson CJ, Srinivasan S, Swern AS, Rifkin RM. Abonour R, et al. Among authors: rifkin rm. Ann Hematol. 2018 Dec;97(12):2425-2436. doi: 10.1007/s00277-018-3446-y. Epub 2018 Jul 29. Ann Hematol. 2018. PMID: 30056582 Free PMC article. Clinical Trial.
Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study.
Kumar SK, Flinn I, Noga SJ, Hari P, Rifkin R, Callander N, Bhandari M, Wolf JL, Gasparetto C, Krishnan A, Grosman D, Glass J, Sahovic EA, Shi H, Webb IJ, Richardson PG, Rajkumar SV. Kumar SK, et al. Leukemia. 2010 Jul;24(7):1350-6. doi: 10.1038/leu.2010.116. Epub 2010 May 27. Leukemia. 2010. PMID: 20508619 Free PMC article. Clinical Trial.
Connect MM® - the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide.
Rifkin RM, Abonour R, Shah JJ, Mehta J, Narang M, Terebelo H, Gasparetto C, Toomey K, Hardin JW, Lu JJ, Kenvin L, Srinivasan S, Knight R, Nagarwala Y, Durie BG. Rifkin RM, et al. Leuk Lymphoma. 2016 Sep;57(9):2228-31. doi: 10.3109/10428194.2015.1132419. Epub 2016 Jan 13. Leuk Lymphoma. 2016. PMID: 26766599 No abstract available.
Recognition of early mortality in multiple myeloma by a prediction matrix.
Terebelo H, Srinivasan S, Narang M, Abonour R, Gasparetto C, Toomey K, Hardin JW, Larkins G, Kitali A, Rifkin RM, Shah JJ. Terebelo H, et al. Among authors: rifkin rm. Am J Hematol. 2017 Sep;92(9):915-923. doi: 10.1002/ajh.24796. Epub 2017 Jul 19. Am J Hematol. 2017. PMID: 28543165 Free PMC article. Clinical Trial.
Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes.
Shah JJ, Abonour R, Gasparetto C, Hardin JW, Toomey K, Narang M, Srinivasan S, Kitali A, Zafar F, Flick ED, Rifkin RM. Shah JJ, et al. Among authors: rifkin rm. Clin Lymphoma Myeloma Leuk. 2017 Sep;17(9):575-583.e2. doi: 10.1016/j.clml.2017.06.013. Epub 2017 Jun 17. Clin Lymphoma Myeloma Leuk. 2017. PMID: 28886839
Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016).
Jagannath S, Abonour R, Durie BGM, Gasparetto C, Hardin JW, Narang M, Terebelo HR, Toomey K, Wagner L, Srinivasan S, Kitali A, Yue L, Flick ED, Agarwal A, Rifkin RM. Jagannath S, et al. Among authors: rifkin rm. Clin Lymphoma Myeloma Leuk. 2018 Jul;18(7):480-485.e3. doi: 10.1016/j.clml.2018.04.007. Epub 2018 May 4. Clin Lymphoma Myeloma Leuk. 2018. PMID: 29844008 Free article.
84 results